Obesity & Diabetes Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity & Diabetes Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cardiology
OXIS Phase IIA licensed compound reduces damage from heart attack in diabetic mice
December 11th, 2006
OXIS International, Inc. (OXIS) commented on an earlier announcement by Alteon (ALT) that BXT-51072 (ALT-2074), a compound that OXIS developed and subsequently licensed to Alteon, has been shown to significantly reduce the myocardial damage in a diabetic mouse heart injury model. BXT-51072 (ALT-2074), licensed by OXIS to Alteon in September 2004, is a low molecular weight oral drug that mimics the antioxidant enzyme glutathione peroxidase. It directly neutralizes hydrogen peroxide and appears to protect cells from oxidative and inflammatory damage. OXIS previously completed a multicenter, nonrandomized, open-label, two-arm clinical trial, which...
Source: Obesity & Diabetes Week (2006-12-11)
|
